{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.1"},{"groupId":"OG001","value":"63.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"425"},{"groupId":"OG001","value":"425"}],"units":"Participants"}],"groups":[{"description":"Docetaxel 75 milligrams per square meter (mg/m\\^2) was administered intravenously (IV) on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.","id":"OG000","title":"Docetaxel"},{"description":"Atezolizumab 1200 mg was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.","id":"OG001","title":"Atezolizumab"}],"paramType":"NUMBER","populationDescription":"PP-ITT analysis set included the first 850 randomized ITT participants regardless of whether they received any study drug.","reportingStatus":"POSTED","timeFrame":"Baseline until death due to any cause (up to approximately 2.25 years)","title":"Percentage of Participants Who Died: PP-ITT","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}